Year : 2017 | Volume
: 37 | Issue : 2 | Page : 43--48
Effectiveness and safety of fexofenadine in chronic idiopathic urticaria − open-label noncomparative study in daily practice
Michel Fouad, Magdy Ragab
Dermatology and Venerology Department, Alex University, Alex, Egypt
This study aimed to evaluate effectiveness and safety of fexofenadine in the treatment of chronic idiopathic urticaria (CIU) in routine practice in Egypt.
Patients and methods
This study is a local, multicenter, noninterventional, prospective, open-label, noncomparative, observational product registry conducted across Egypt. Three mandatory visits were made by the investigator for each eligible patient, and patients were assessed by urticaria symptoms score.
The results of this study showed a statistically significant reduction (P<0.001) in signs and symptoms of CIU evaluated by the urticaria-related signs and symptoms score according to patients’ completed diary cards. Pruritis was decreased in 74.9% of patients and was improved in 22.3% of patients. Hives were relieved in 81.1% of patients and were improved in 17.5% of patients, whereas other related signs and symptoms of CIU were decreased in 75.5% of patients and improved in 22.2% of patients. Mild dizziness was reported in 0.2% of total enrolled patients that recovered after 3 days without corrective treatment.
Fexofenadine demonstrated statistically significant reduction in symptoms and signs of CIU. Pruritis status was decreased in 74.95% of patients. Hives status were relieved in 81.1% of patients, after a mean treatment duration of 14.93±5.49 days at visit 2 and 27.94±4.56 days at visit 3 (end of study). In addition, treatment with fexofenadine was well tolerated.
Dermatology and Venerology Department, Alex University, 28 alt Basha Zolfakar Roshdy Alex
|How to cite this article:|
Fouad M, Ragab M. Effectiveness and safety of fexofenadine in chronic idiopathic urticaria − open-label noncomparative study in daily practice.Egypt J Dermatol Venerol 2017;37:43-48
|How to cite this URL:|
Fouad M, Ragab M. Effectiveness and safety of fexofenadine in chronic idiopathic urticaria − open-label noncomparative study in daily practice. Egypt J Dermatol Venerol [serial online] 2017 [cited 2018 Jan 22 ];37:43-48
Available from: http://www.ejdv.eg.net/article.asp?issn=1110-6530;year=2017;volume=37;issue=2;spage=43;epage=48;aulast=Fouad;type=0